Discover
Stelara (ustekinumab) / J&JStelara: “The Committee confirmed that all issues previously identified in this application had been addressed [Moderate to severe psoriasis]” (EMEA) - Mar 3, 2020 - CHMP Final Minutes of the meeting on 9-12 December 2019: “The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable”
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimPlaque psoriasis: Reimbursement for risankizumab [Google translation] (Corriere Nazionale) - Mar 8, 2020 - "The Italian Medicines Agency (Aifa) has approved the reimbursement in Italy of risankizumab for the treatment of moderate to severe plaque psoriasis in adult patients candidates for systemic therapy. Risankizumab can be administered by two subcutaneous injections every 12 weeks, after two starting doses administered at week 0 and week 4."
BMS-986165 / BMSAn Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis (clinicaltrials.gov) - Mar 4, 2020 - P3; N=80; Active, not recruiting; Sponsor: Bristol-Myers Squibb; Recruiting --> Active, not recruiting
KD025 / Kadmon, Romeck PharmaKD025: Expiry of patents related to composition-of-matter and method of use for fibrosis in US in 2029 and Canada, China, Eurasia, Europe, and Japan in 2026. (Kadmon) - Mar 6, 2020 - Annual Report 2019: Expiry of patents related to method of use for cGVHD in US in 2035 and for immune diseases including GVHD in US, Japan, Canada, China, Eurasia, and Europe in 2033 [Screenshot]
piclidenoson (CF101) / Can-Fite, China Medical SystemCan-Fite is filing drug safety update report showing positive safety results from phase II and phase III studies of namodenoson and piclidenoson (Businesswire) - Mar 3, 2020 - "Can-Fite is filing drug safety update report showing positive safety results from phase-Can-Fite BioPharma Ltd....today announced it is submitting its annual Drug Safety Update Reports (DSUR) for both Piclidenoson and Namodenoson to the governing health regulatory agencies where its drug candidates are currently treating patients....Can-Fite’s reports being filed this year extend the growing body of documentation showing both Piclidenoson and Namodenoson have favorable safety profiles and risk-benefit ratios in more than 1,500 patients."
RTA 1701 / ReataRTA 1701: Expiry of patents related to composition-of-matter and method of use claims in US/ex-US between 2031- 2037 (Reata) - Mar 5, 2020 - Annual Report 2019
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimThe Interministerial Commission modifies the price of 50 medicines (Acta Sanitaria) - Mar 6, 2020 - "The Interministerial Commission for the Prices of Medicines (CIPM), at its meeting held on February 4, approved three new drugs and decided to review the price of 50...as stated in the information provided by the Ministry of Health....According to the minutes of the CIPM meeting, the Commission approved three new medicines (Skyrizi, from Abbvie...The price set for this drug is € 3,833.49."
